AMLX logo

AMLX
Amylyx Pharmaceuticals Inc

2,153
Mkt Cap
$1.72B
Volume
1.07M
52W High
$18.61
52W Low
$4.20
PE Ratio
-10.05
AMLX Fundamentals
Price
$16.00
Prev Close
$15.60
Open
$15.63
50D MA
$15.20
Beta
1.75
Avg. Volume
1.06M
EPS (Annual)
-$1.53
P/B
5.62
Rev/Employee
$0.00
$831.33
Loading...
Loading...
News
all
press releases
Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) will report its first quarter 2026 financial results on Thursday, May 7, 2026. Amylyxs senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates...
Business Wire·9h ago
News Placeholder
More News
News Placeholder
Amylyx Pharmaceuticals (AMLX) Projected to Post Quarterly Earnings on Thursday
Amylyx Pharmaceuticals (NASDAQ:AMLX) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...
MarketBeat·11h ago
News Placeholder
Mizuho Forecasts Strong Price Appreciation for Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock
Mizuho increased their price objective on Amylyx Pharmaceuticals from $19.00 to $21.00 and gave the stock an "outperform" rating in a research note on Tuesday...
MarketBeat·2d ago
News Placeholder
Stock Traders Purchase High Volume of Call Options on Amylyx Pharmaceuticals (NASDAQ:AMLX)
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) was the target of some unusual options trading activity on Monday. Traders bought 3,000 call options on the stock. This is an increase of...
MarketBeat·10d ago
News Placeholder
Amylyx Pharmaceuticals (NASDAQ:AMLX) Reaches New 12-Month High - Should You Buy?
Amylyx Pharmaceuticals (NASDAQ:AMLX) Reaches New 52-Week High - Time to Buy...
MarketBeat·14d ago
News Placeholder
Amylyx Pharmaceuticals Sets Up Q3 Phase 3 Avexitide Data Readout, Eyes Potential 2027 Launch
Amylyx Pharmaceuticals (NASDAQ:AMLX) is entering what it described as a pivotal year for its lead program, avexitide, with Phase 3 data expected in the third quarter and preparations underway for a...
MarketBeat·15d ago
News Placeholder
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Recommendation of "Moderate Buy" from Brokerages
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the fourteen research firms that are covering the company, Marketbeat...
MarketBeat·21d ago
News Placeholder
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK...
PR Newswire·21d ago
News Placeholder
Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference. The corporate presentation...
Business Wire·22d ago
News Placeholder
Amylyx Pharmaceuticals (NASDAQ:AMLX) Shares Up 6.9% - What's Next?
Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading Up 6.9% - Should You Buy...
MarketBeat·24d ago
<
1
2
...
>

Latest AMLX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.